Overview
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
Description
If portal vein thrombosis occurs more than one year after and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, the efficacy of apixaban in treating portal vein thrombosis will be examined every three months using Doppler ultrasound screening or contrast-enhanced CT scans. If it is effective, the patient will continue to take apixaban.
Eligibility
Inclusion Criteria:
- Female patients
- Diagnosis of Fibromyalgia Syndrome according to 2016 criteria
- Muscle pain Visual Analogue Scale (VAS) score greater than 5 in the last month
- Age between 18 and 60 years
- Absence of other chronic, widespread, or localized painful conditions
- Absence of any other condition that might affect pain perception (e.g., diabetes)
- Absence of neurological or psychiatric conditions that might affect study participation
- Absence of current or past oncological diseases in the last 5 years
- Absence of corticosteroid therapy in the last 30 days
- Absence of NSAID (Non-Steroidal Anti-Inflammatory Drugs) and analgesic therapy in the last 4 days
- Absence of pregnancy and breastfeeding for the entire duration of observation
- Signed informed consent
Exclusion Criteria:
- Presence of severe scoliosis or kyphoscoliosis
- Previous spinal surgeries or sequelae of vertebral fractures
- Presence of lumbosciatalgia (sciatica-like pain in the lower back) at the time of the visit
- Presence of osteoporosis
- Presence of neurological or psychiatric conditions
- Current therapy with corticosteroids and/or NSAIDs and/or analgesics
- Pregnancy or breastfeeding
